{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:51:56Z","timestamp":1785455516264,"version":"3.56.0"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL107110"],"award-info":[{"award-number":["R01 HL107110"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 HL134558"],"award-info":[{"award-number":["1R01 HL134558"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5UM 1HL113460"],"award-info":[{"award-number":["5UM 1HL113460"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL137355"],"award-info":[{"award-number":["R01 HL137355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["NHLBI-ECB-HB-2016-09-JB"],"award-info":[{"award-number":["NHLBI-ECB-HB-2016-09-JB"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["4UM1HL087318-10"],"award-info":[{"award-number":["4UM1HL087318-10"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["PCT0013-01"],"award-info":[{"award-number":["PCT0013-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["PCT0004-02"],"award-info":[{"award-number":["PCT0004-02"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["PCT0009-01"],"award-info":[{"award-number":["PCT0009-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Left ventricular hypertrophy and heart failure with preserved ejection fraction (HFpEF) are primary manifestations of the cardiorenal syndrome in patients with chronic kidney disease (CKD). Therapies that improve morbidity and mortality in HFpEF are lacking. Cell-based therapies promote cardiac repair in ischemic and non-ischemic cardiomyopathies. We hypothesized that cell-based therapy ameliorates CKD-induced HFpEF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and Results<\/jats:title>\n                  <jats:p>Yorkshire pigs (n = 26) underwent 5\/6 embolization-mediated nephrectomy. CKD was confirmed by increased creatinine and decreased glomerular filtration rate (GFR). Mean arterial pressure (MAP) was not different between groups from baseline to 4 weeks. HFpEF was evident at 4 weeks by increased LV mass, relative wall thickening, end-diastolic pressure, and end-diastolic pressure-volume relationship, with no change in ejection fraction (EF). Four weeks post-embolization, allogeneic (allo) bone marrow-derived mesenchymal stem cells (MSC; 1\u00a0\u00d7\u00a0107 cells), allo-kidney-derived stem cells (KSC; 1\u00a0\u00d7\u00a0107 cells), allo-cell combination therapy (ACCT; MSC + KSC; 1:1 ratio; total = 1\u00a0\u00d7\u00a0107 cells), or placebo (Plasma-Lyte) was delivered via intra-renal artery. Eight weeks post-treatment, there was a significant increase in MAP in the placebo group (21.89\u00a0\u00b1\u00a06.05 mmHg) compared to the ACCT group. GFR significantly improved in the ACCT group. EF, relative wall thickness, and LV mass did not differ between groups at 12 weeks. EDPVR improved in the ACCT group, indicating decreased ventricular stiffness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intra-renal artery allogeneic cell therapy was safe in a CKD swine model manifesting the characteristics of HFpEF. The beneficial effect on renal function and ventricular compliance in the ACCT group supports further research of cell therapy for cardiorenal syndrome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/stcltm\/szab004","type":"journal-article","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T04:49:14Z","timestamp":1641012554000},"page":"59-72","source":"Crossref","is-referenced-by-count":7,"title":["Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1093","volume":"11","author":[{"given":"Angela C","family":"Rieger","sequence":"first","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryon A","family":"Tompkins","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"},{"name":"Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-7274","authenticated-orcid":false,"given":"Makoto","family":"Natsumeda","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Florea","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monisha N","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"},{"name":"Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Rosado","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Porras","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystalenia","family":"Valasaki","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauro M","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Collon","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohil","family":"Desai","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Bellio","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Khan","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh D","family":"Kashikar","sequence":"additional","affiliation":[{"name":"Aurora Diagnostics GPA Laboratories (ADXGPA), Greensboro, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Marie","family":"Landin","sequence":"additional","affiliation":[{"name":"Cell Therapy and Vaccine Lab, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell V","family":"Hardin","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"},{"name":"Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-0489","authenticated-orcid":false,"given":"Wayne","family":"Balkan","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"},{"name":"Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M","family":"Hare","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"},{"name":"Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne Hernandez","family":"Schulman","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA"},{"name":"Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,19]]},"reference":[{"issue":"3","key":"2022030315204826500_CIT0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction.","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med."},{"issue":"10","key":"2022030315204826500_CIT0002","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association.","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation."},{"issue":"10","key":"2022030315204826500_CIT0003","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction.","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol."},{"issue":"12","key":"2022030315204826500_CIT0004","doi-asserted-by":"crossref","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial.","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"1","key":"2022030315204826500_CIT0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","article-title":"Medical therapies for heart failure with preserved ejection fraction.","volume":"75","author":"Kjeldsen","year":"2020","journal-title":"Hypertension."},{"key":"2022030315204826500_CIT0006","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med."},{"issue":"Suppl 9","key":"2022030315204826500_CIT0007","first-page":"ix19","article-title":"Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease","volume":"22","author":"Daly","year":"2007","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"2022030315204826500_CIT0008","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000101028","article-title":"The impact of living donor kidney transplantation on markers of cardiovascular risk in chronic kidney disease patients.","volume":"25","author":"Bignelli","year":"2007","journal-title":"Blood Purif."},{"issue":"Suppl 1","key":"2022030315204826500_CIT0009","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.2215\/CJN.04860709","article-title":"Left ventricular mass in chronic kidney disease and ESRD.","volume":"4","author":"Glassock","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7","key":"2022030315204826500_CIT0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2004.11.061","article-title":"Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease.","volume":"45","author":"Wali","year":"2005","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"2022030315204826500_CIT0011","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy.","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest."},{"issue":"19","key":"2022030315204826500_CIT0012","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation."},{"key":"2022030315204826500_CIT0013","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ki.2008.516","article-title":"Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease","volume":"74","author":"Cachofeiro","year":"2008","journal-title":"Kidney Int."},{"issue":"1","key":"2022030315204826500_CIT0014","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/CIRCRESAHA.115.302929","article-title":"Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium.","volume":"115","author":"Loffredo","year":"2014","journal-title":"Circ Res."},{"issue":"3","key":"2022030315204826500_CIT0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction.","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation."},{"issue":"7","key":"2022030315204826500_CIT0016","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.ymthe.2018.05.009","article-title":"Mesenchymal stem cell-based therapy for cardiovascular disease: progress and challenges.","volume":"26","author":"Bagno","year":"2018","journal-title":"Mol Ther."},{"issue":"20","key":"2022030315204826500_CIT0017","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2017.09.036","article-title":"A combination of allogeneic stem cells promotes cardiac regeneration.","volume":"70","author":"Natsumeda","year":"2017","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"2022030315204826500_CIT0018","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial.","volume":"69","author":"Hare","year":"2017","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"2022030315204826500_CIT0019","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/CIRCRESAHA.117.311827","article-title":"Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study).","volume":"121","author":"Florea","year":"2017","journal-title":"Circ Res."},{"issue":"1","key":"2022030315204826500_CIT0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.","volume":"311","author":"Heldman","year":"2014","journal-title":"JAMA."},{"issue":"22","key":"2022030315204826500_CIT0021","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA."},{"issue":"7","key":"2022030315204826500_CIT0022","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/CIRCRESAHA.110.222703","article-title":"Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.","volume":"107","author":"Hatzistergos","year":"2010","journal-title":"Circ Res."},{"issue":"5","key":"2022030315204826500_CIT0023","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ebiom.2015.03.020","article-title":"Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells.","volume":"2","author":"Premer","year":"2015","journal-title":"EBioMedicine."},{"issue":"33","key":"2022030315204826500_CIT0024","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1073\/pnas.0903201106","article-title":"Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity.","volume":"106","author":"Quevedo","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"issue":"18","key":"2022030315204826500_CIT0025","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.jacc.2015.08.879","article-title":"Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy.","volume":"66","author":"Karantalis","year":"2015","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"2022030315204826500_CIT0026","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.114.303180","article-title":"Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: the prospective randomized study of mesenchymal stem cell therapy in patients undergoing cardiac surgery (PROMETHEUS) trial.","volume":"114","author":"Karantalis","year":"2014","journal-title":"Circ Res."},{"issue":"32","key":"2022030315204826500_CIT0027","doi-asserted-by":"crossref","first-page":"11474","DOI":"10.1073\/pnas.0504388102","article-title":"Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction.","volume":"102","author":"Amado","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"issue":"8","key":"2022030315204826500_CIT0028","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/stem.1412","article-title":"c-Kit+ cells isolated from developing kidneys are a novel population of stem cells with regenerative potential.","volume":"31","author":"Rangel","year":"2013","journal-title":"Stem Cells."},{"issue":"4","key":"2022030315204826500_CIT0029","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/sctm.17-0232","article-title":"Kidney-derived c-Kit+ cells possess regenerative potential.","volume":"7","author":"Gomes","year":"2018","journal-title":"Stem Cells Transl Med."},{"issue":"1","key":"2022030315204826500_CIT0030","doi-asserted-by":"crossref","first-page":"14723","DOI":"10.1038\/s41598-018-33082-x","article-title":"Kidney-derived c-kit+ progenitor\/stem cells contribute to podocyte recovery in a model of acute proteinuria.","volume":"8","author":"Rangel","year":"2018","journal-title":"Sci Rep."},{"issue":"9","key":"2022030315204826500_CIT0031","doi-asserted-by":"crossref","first-page":"H1390","DOI":"10.1152\/ajpheart.00713.2015","article-title":"A new porcine model of hypertensive cardiomyopathy: a helpful tool to explore the HFpEF mystique.","volume":"309","author":"Hu","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"9","key":"2022030315204826500_CIT0032","doi-asserted-by":"crossref","first-page":"H1407","DOI":"10.1152\/ajpheart.00542.2015","article-title":"A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction.","volume":"309","author":"Schwarzl","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"4","key":"2022030315204826500_CIT0033","doi-asserted-by":"crossref","first-page":"e2019835118","DOI":"10.1073\/pnas.2019835118","article-title":"Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction","volume":"118","author":"Rieger","year":"2021","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"2022030315204826500_CIT0034","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jss.2006.04.001","article-title":"The porcine remnant kidney model of chronic renal insufficiency.","volume":"135","author":"Misra","year":"2006","journal-title":"J Surg Res."},{"issue":"1","key":"2022030315204826500_CIT0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000499486","article-title":"Consequences of glomerular hyperfiltration: the role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity.","volume":"143","author":"Chagnac","year":"2019","journal-title":"Nephron."},{"issue":"10","key":"2022030315204826500_CIT0036","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1097\/TP.0000000000002304","article-title":"Hyperfiltration-mediated injury in the remaining kidney of a transplant donor.","volume":"102","author":"Srivastava","year":"2018","journal-title":"Transplantation."},{"issue":"1","key":"2022030315204826500_CIT0037","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.RVI.0000052296.26939.4c","article-title":"Pathologic evaluation of a spherical polyvinyl alcohol embolic agent in a porcine renal model.","volume":"14","author":"Siskin","year":"2003","journal-title":"J Vasc Interv Radiol."},{"key":"2022030315204826500_CIT0038","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-62703-505-7_8","article-title":"Cell-based therapies for myocardial repair: emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart.","volume":"1037","author":"Da Silva","year":"2013","journal-title":"Methods Mol Biol."},{"issue":"7","key":"2022030315204826500_CIT0039","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/CIRCRESAHA.111.242610","article-title":"Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling.","volume":"108","author":"Williams","year":"2011","journal-title":"Circ Res."},{"key":"2022030315204826500_CIT0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-60761-705-1_5","article-title":"Mesenchymal stem cell therapy for cardiac repair.","volume":"660","author":"Boyle","year":"2010","journal-title":"Methods Mol Biol."},{"issue":"10","key":"2022030315204826500_CIT0041","doi-asserted-by":"crossref","first-page":"e003238","DOI":"10.1161\/CIRCHEARTFAILURE.115.003238","article-title":"Left atrial remodeling and atrioventricular coupling in a canine model of early heart failure with preserved ejection fraction","volume":"9","author":"Zakeri","year":"2016","journal-title":"Circ Heart Fail."},{"key":"2022030315204826500_CIT0042","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/cvr\/cvt144","article-title":"Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts","volume":"99","author":"M\u00fcller","year":"2013","journal-title":"Cardiovasc Res."},{"issue":"6","key":"2022030315204826500_CIT0043","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/CIRCRESAHA.108.193326","article-title":"Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium.","volume":"104","author":"Borb\u00e9ly","year":"2009","journal-title":"Circ Res."},{"issue":"8","key":"2022030315204826500_CIT0044","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail."},{"issue":"30","key":"2022030315204826500_CIT0045","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Heart failure with preserved ejection fraction: from mechanisms to therapies.","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J."},{"issue":"5","key":"2022030315204826500_CIT0046","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF.","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation."},{"issue":"14","key":"2022030315204826500_CIT0047","doi-asserted-by":"crossref","first-page":"e008460","DOI":"10.1161\/JAHA.117.008460","article-title":"Comparison of mesenchymal stem cell efficacy in ischemic versus nonischemic dilated cardiomyopathy","volume":"7","author":"Tompkins","year":"2018","journal-title":"J Am Heart Assoc."},{"issue":"14","key":"2022030315204826500_CIT0048","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1161\/CIRCULATIONAHA.106.659730","article-title":"Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling.","volume":"115","author":"Zeng","year":"2007","journal-title":"Circulation."},{"issue":"3","key":"2022030315204826500_CIT0049","doi-asserted-by":"crossref","first-page":"H1772","DOI":"10.1152\/ajpheart.00242.2007","article-title":"Functional and bioenergetic modulations in the infarct border zone following autologous mesenchymal stem cell transplantation.","volume":"293","author":"Feygin","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"7","key":"2022030315204826500_CIT0050","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.ymthe.2018.05.009","article-title":"Mesenchymal stem cell-based therapy for cardiovascular disease: progress and challenges.","volume":"26","author":"Bagno","year":"2018","journal-title":"Mol Ther."},{"key":"2022030315204826500_CIT0051","doi-asserted-by":"crossref","first-page":"147238","DOI":"10.1038\/s41598-018-33082-x","article-title":"Kidney-derived c-kit+ progenitor\/stem cells contribute to podocyte recovery in a model of acute proteinuria.","volume":"8","author":"Rangel","year":"2018","journal-title":"Sci Rep."},{"key":"2022030315204826500_CIT0052","volume-title":"Stem Cell Therapies for Renal Diseases. Reference Module in Biomedical Sciences","author":"Rieger","year":"2019"},{"issue":"2","key":"2022030315204826500_CIT0053","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.ki.5000031","article-title":"Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease.","volume":"69","author":"Chade","year":"2006","journal-title":"Kidney Int."},{"issue":"6","key":"2022030315204826500_CIT0054","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.","volume":"18","author":"Ter Maaten","year":"2016","journal-title":"Eur J Heart Fail."},{"issue":"25","key":"2022030315204826500_CIT0055","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","article-title":"Plasma cytokine parameters and mortality in patients with chronic heart failure.","volume":"102","author":"Rauchhaus","year":"2000","journal-title":"Circulation."},{"issue":"4","key":"2022030315204826500_CIT0056","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"2022030315204826500_CIT0057","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/scrt541","article-title":"Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease.","volume":"6","author":"Eirin","year":"2015","journal-title":"Stem Cell Res Ther."},{"issue":"4","key":"2022030315204826500_CIT0058","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.kint.2016.05.026","article-title":"Hypoxia-inducible factor-1\u03b1 promotes glomerulosclerosis and regulates COL1A2 expression through interactions with Smad3.","volume":"90","author":"Baumann","year":"2016","journal-title":"Kidney Int."},{"issue":"4","key":"2022030315204826500_CIT0059","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000449323","article-title":"Hypoxia-inducible factor-1\u03b1 activates the transforming growth factor-\u03b2\/SMAD3 pathway in kidney tubular epithelial cells.","volume":"44","author":"Kushida","year":"2016","journal-title":"Am J Nephrol."},{"issue":"6","key":"2022030315204826500_CIT0060","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.","volume":"31","author":"Siragy","year":"2010","journal-title":"Am J Nephrol."},{"issue":"9","key":"2022030315204826500_CIT0061","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1681\/ASN.2017020151","article-title":"Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease.","volume":"28","author":"Saad","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"2022030315204826500_CIT0062","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.kint.2019.11.022","article-title":"In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.","volume":"97","author":"Abumoawad","year":"2020","journal-title":"Kidney Int."},{"issue":"5","key":"2022030315204826500_CIT0063","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2362.2002.00985.x","article-title":"Myocardial fibrosis in transforming growth factor-\u03b21 (TGF-\u03b21) transgenic mice is associated with inhibition of interstitial collagenase.","volume":"32","author":"Seeland","year":"2002","journal-title":"Eur J Clin Invest."},{"issue":"1","key":"2022030315204826500_CIT0064","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/01.CIR.0000020689.12472.E0","article-title":"Transforming growth factor-\u03b2 function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats.","volume":"106","author":"Kuwahara","year":"2002","journal-title":"Circulation."},{"issue":"11","key":"2022030315204826500_CIT0065","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.","volume":"56","author":"Borlaug","year":"2010","journal-title":"J Am Coll Cardiol."},{"issue":"19","key":"2022030315204826500_CIT0066","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1161\/01.CIR.98.19.2065","article-title":"Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats.","volume":"98","author":"Iwanaga","year":"1998","journal-title":"Circulation."},{"issue":"4","key":"2022030315204826500_CIT0067","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","article-title":"Transforming growth factor (TGF)-\u03b2 signaling in cardiac remodeling.","volume":"51","author":"Dobaczewski","year":"2011","journal-title":"J Mol Cell Cardiol."},{"issue":"16","key":"2022030315204826500_CIT0068","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.jacc.2015.08.023","article-title":"Reverse remodeling and prognosis following kidney transplantation in contemporary patients with cardiac dysfunction.","volume":"66","author":"Hawwa","year":"2015","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"2022030315204826500_CIT0069","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ajh.2010.259","article-title":"Reversal of experimental renovascular hypertension restores coronary microvascular function and architecture.","volume":"24","author":"Urbieta-Caceres","year":"2011","journal-title":"Am J Hypertens."},{"issue":"2","key":"2022030315204826500_CIT0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gft305","article-title":"Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis.","volume":"29","author":"Eirin","year":"2014","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"2022030315204826500_CIT0071","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1681\/ASN.2006090976","article-title":"Simvastatin prevents coronary microvascular remodeling in renovascular hypertensive pigs.","volume":"18","author":"Zhu","year":"2007","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"2022030315204826500_CIT0072","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/CIRCRESAHA.114.305495","article-title":"Allogeneic cell therapy: a new paradigm in therapeutics.","volume":"116","author":"Karantalis","year":"2015","journal-title":"Circ Res."},{"issue":"1","key":"2022030315204826500_CIT0073","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12015-011-9345-4","article-title":"Multipotent mesenchymal stromal cell therapy and risk of malignancies.","volume":"9","author":"Casiraghi","year":"2013","journal-title":"Stem Cell Rev Rep."},{"issue":"2","key":"2022030315204826500_CIT0074","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCULATIONAHA.112.131110","article-title":"Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction.","volume":"127","author":"Williams","year":"2013","journal-title":"Circulation."},{"issue":"12","key":"2022030315204826500_CIT0075","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCRESAHA.118.312978","article-title":"Rationale and design of the CONCERT-HF trial (combination of mesenchymal and c-kit+ cardiac stem cells as regenerative therapy for heart failure).","volume":"122","author":"Bolli","year":"2018","journal-title":"Circ Res."},{"issue":"4","key":"2022030315204826500_CIT0076","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ejhf.2178","article-title":"A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.","volume":"23","author":"Bolli","year":"2021","journal-title":"Eur J Heart Fail."}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/11\/1\/59\/42689957\/szab004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/11\/1\/59\/42689957\/szab004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T15:22:07Z","timestamp":1646320927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/11\/1\/59\/6532408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,19]]},"published-print":{"date-parts":[[2022,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szab004","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]}}}